Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 3/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.51 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8640906 | 0.92 | LMNA (0.59) | LMNAALDH1A1SMN1; SMN2POLBMAPK1 | |
| SCHEMBL28281220 | 0.82 | LMNA (0.65) | LMNAALDH1A1SMN1; SMN2POLBMAPK1 | |
| SCHEMBL1756761 | 0.82 | LMNA (0.53) | LMNAALDH1A1SMN1; SMN2POLBMAPK1 | |
| SCHEMBL17026753 | 0.81 | LMNA (0.47) | LMNAALDH1A1GAAP2RX7KDM4E | |
| SCHEMBL11242556 | 0.81 | LMNA (0.63) | LMNAALDH1A1SMN1; SMN2POLBMAPK1 | |
| SCHEMBL5015977 | 0.78 | OPRM1 (0.74) | LMNANPSR1OPRM1OPRD1TP53 | |
| SCHEMBL6367594 | 0.78 | LMNA (0.60) | LMNAALDH1A1SMN1; SMN2POLBMAPK1 | |
| SCHEMBL8667475 | 0.78 | ALOX5 (0.50) | LMNAALDH1A1GAAP2RX7MEN1 | |
| SCHEMBL10083664 | 0.77 | LMNA (1.00) | LMNAALDH1A1SMN1; SMN2POLBMAPK1 | |
| SCHEMBL2861616 | 0.77 | LMNA (0.58) | LMNAALDH1A1SMN1; SMN2POLBMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-58109455-A | — | — | None | — | — | JP | disclosed |
| US-7973163-B2 | Fused quinoline derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LTD. (JP) | 2011-07-05 | — | — | US | disclosed |
| US-7973163-B2 | Fused quinoline derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LTD. (JP) | 2011-07-05 | — | — | US | disclosed |
| US-7943770-B2 | Fused quinoline derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-17 | — | — | US | disclosed |
| US-7943770-B2 | Fused quinoline derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-17 | — | — | US | disclosed |
| US-7943770-B2 | Fused quinoline derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-17 | — | — | US | disclosed |
| EP-1740584-B9 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2010-06-09 | — | — | EP | disclosed |
| US-20090275568-A1 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-05 | — | — | US | disclosed |
| US-20090275568-A1 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-05 | — | — | US | disclosed |
| US-20090275568-A1 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-05 | — | — | US | disclosed |
| US-7592453-B2 | Fused quinoline derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-22 | — | — | US | disclosed |
| EP-2080760-A1 | Fused quinoline derivative and use thereof | Takeda Pharmaceutical Company Limited (JP) | 2009-07-22 | — | — | EP | disclosed |
| EP-1740584-B1 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2008-12-03 | — | — | EP | disclosed |
| US-20080039452-A1 | Fused Quinoline Derivative and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-02-14 | — | — | US | disclosed |
| US-20080039452-A1 | Fused Quinoline Derivative and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-02-14 | — | — | US | disclosed |
| US-20080039452-A1 | Fused Quinoline Derivative and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-02-14 | — | — | US | disclosed |
| CN-1976932-A | Fused quinoline derivative and use thereof | TAKEDA PHARMACEUTICAL (JP) | 2007-06-06 | — | — | CN | disclosed |
| EP-1740584-A1 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005105802-A1 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-11-10 | — | — | WO | disclosed |
| JP-S58109455-A | N-BENZYL AMINO ACID DERIVATIVE AND ITS PREPARATION | KUREHA CHEM IND CO LTD | 1983-06-29 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275568-A1 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF | TACR2, HRH3, HRH2 | LMNA 3999/4885ALDH1A1 2927/4885SMN1; SMN2 3748/4885 |
| US-20080039452-A1 | Fused Quinoline Derivative and Use Thereof | TACR2, HRH3, HRH2 | LMNA 4027/4885ALDH1A1 2917/4885SMN1; SMN2 3715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.